- Accesswire•3 days agoBull Market Ahead for the Biotech Industry in 2017? Today's Reports on Sarepta Therapeutics and Galectin Therapeutics
NEW YORK, NY / ACCESSWIRE / February 22, 2017 / The Biotech Industry's rally does not appear to be losing any steam in 2017. Both the iShares NASDAQ Biotechnology Index ETF and the SPDR S&P Biotech ETF ...
- GlobeNewswire•17 days ago
NORCROSS, Ga., Feb. 08, 2017-- Galectin Therapeutics Inc., the leading developer of therapeutics that target galectin proteins, today announced that Harold Shlevin, Ph.D., the Company’ s chief operating ...
- GlobeNewswire•18 days agoCombination Immunotherapy with Galectin-3 Inhibitor GR-MD-02 Enhances Effects in Pre-clinical Models and Early Results of Phase 1 Clinical Trials
NORCROSS, Ga., Feb. 07, 2017-- Galectin Therapeutics Inc., the leading developer of therapeutics that target galectin proteins, and the Providence Cancer Center today announced the presentation of preclinical ...
GALT : Summary for Galectin Therapeutics Inc. - Yahoo Finance
Galectin Therapeutics, Inc. (GALT)
NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
|Bid||1.65 x 10000|
|Ask||2.00 x 1000|
|Day's Range||1.72 - 1.90|
|52 Week Range||0.49 - 3.05|
Trade prices are not sourced from all markets
|PE Ratio (TTM)||-2.29|
|Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|